Nuvation Bio Inc.
18
4
7
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.8%
5 terminated/withdrawn out of 18 trials
50.0%
-36.5% vs industry average
17%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Role: lead
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Role: lead
A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Role: collaborator
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Role: lead
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Role: lead
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Role: lead
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Role: lead
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Role: lead
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
Role: lead
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Role: collaborator
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Role: lead
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Role: lead
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
Role: lead
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
Role: lead
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
Role: lead
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Role: lead
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Role: lead
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Role: lead
All 18 trials loaded